Dr. Marco Ruella is a physician-scientist and assistant professor at the University of Pennsylvania. He treats patients with blood cancers and focuses on using immunotherapy, where the body’s own immune system is harnessed to fight cancer. His research looks at why some cancers return after CAR T-cell therapy and aims to design new treatments to prevent this. Dr. Ruella earned his medical degree in Italy and completed advanced training in the U.S. He has received many awards for his work, including from the American Society for Clinical Investigation and the Leukemia & Lymphoma Society. Dr. Ruella has published widely, holds multiple patents, and advises companies in cancer immunotherapy. He also founded viTToria Biotherapeutics to help bring new treatments to patients.
Marco Ruella MD
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
United States
Project Title
Precision Targeting of Hairy Cell Leukemia using Chimeric Antigen Receptor T cells A First-in-human Clinical Trial of CD5 knocked-out Chimeric Antigen T Cells for T-cell Lymphomas Building Upon The Success Of CART19: Safe and Effective Next-Generation CART For Relapsed And Refractory Lymphomas β-Hydroxybutyrate To Enhance CAR T Cell Immunotherapy Against Hematological Cancers
Program
HCL2025
Translational Research Program